Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
PPP1R14A
Introduction
Protein phosphatase 1 regulatory subunit 14A also known as CPI-17 (C-kinase potentiated Protein phosphatase-1 Inhibitor Mr = 17 kDa) is a protein that in humans is encoded by the PPP1R14A gene.[1][2][3]
Function
Function
CPI-17 is a phosphorylation-dependent inhibitor protein of smooth muscle myosin phosphatase, discovered in pig aortic homogenetes. Phosphorylation of the Thr-38 residue converts the protein into a potent inhibitor for myosin phosphatase. A single phosphorylation of CPI-17 at Thr-38 triggers a global conformational change that causes re-alignment of four helices. Multiple kinases are identified to phosphorylate CPI-17, such as PKC, ROCK, PKN, ZIPK, ILK, and PAK. Agonist stimulation of smooth muscle enhances CPI-17 phosphorylation mainly through PKC and ROCK. Myosin phosphatase inhibition increases myosin phosphorylation and smooth muscle contraction in the absence of increased intracellular Ca2+ concentration. This phenomenon is known as Ca2+ sensitization, which occurs in response to agonist stimulation of smooth muscle. In Purkinje neuron, CPI-17 is involved in long-term synaptic depression.
There are three homologues of CPI-17:
Clinical significance
Clinical significance
CPI-17 is up-regulated some cancer cells, and causes hyperphosphorylation of tumor suppressor merlin/NF2.[4][3]
References
References
- ↑ Eto M, Ohmori T, Suzuki M, et al. (1996). “A novel protein phosphatase-1 inhibitory protein potentiated by protein kinase C. Isolation from porcine aorta media and characterization”. J. Biochem. 118 (6): 1104–7. PMID 8720121.
- ↑ Yamawaki K, Ito M, Machida H, Moriki N, Okamoto R, Isaka N, Shimpo H, Kohda A, Okumura K, Hartshorne DJ, Nakano T (Jul 2001). “Identification of human CPI-17, an inhibitory phosphoprotein for myosin phosphatase”. Biochem Biophys Res Commun. 285 (4): 1040–5. doi:10.1006/bbrc.2001.5290. PMID 11467857.
- ↑ 3.0 3.1 “Entrez Gene: PPP1R14A protein phosphatase 1, regulatory (inhibitor) subunit 14A”.
- ↑ Eto M; Ohmori, T; Suzuki, M; Furuya, K; Morita, F (2009). “Regulation of Cellular Protein Phosphatase-1 (PP1) by Phosphorylation of the CPI-17 Family, C-kinase-activated PP1 Inhibitors”. J. Biol. Chem. 284 (51): 35273–7. doi:10.1074/jbc.R109.059972. PMC 2790955. PMID 19846560.
Further reading
Further reading
- Eto M, Ohmori T, Suzuki M, et al. (1996). “A novel protein phosphatase-1 inhibitory protein potentiated by protein kinase C. Isolation from porcine aorta media and characterization”. J. Biochem. 118 (6): 1104–7. PMID 8720121.
- Eto M, Senba S, Morita F, Yazawa M (1997). “Molecular cloning of a novel phosphorylation-dependent inhibitory protein of protein phosphatase-1 (CPI17) in smooth muscle: its specific localization in smooth muscle”. FEBS Lett. 410 (2–3): 356–60. doi:10.1016/S0014-5793(97)00657-1. PMID 9237662.
- Koyama M, Ito M, Feng J, et al. (2000). “Phosphorylation of CPI-17, an inhibitory phosphoprotein of smooth muscle myosin phosphatase, by Rho-kinase”. FEBS Lett. 475 (3): 197–200. doi:10.1016/S0014-5793(00)01654-9. PMID 10869555.
- Hamaguchi T, Ito M, Feng J, et al. (2000). “Phosphorylation of CPI-17, an inhibitor of myosin phosphatase, by protein kinase N”. Biochem. Biophys. Res. Commun. 274 (3): 825–30. doi:10.1006/bbrc.2000.3225. PMID 10924361.
- Li Z, Yu L, Zhang Y, et al. (2002). “Identification of human, mouse and rat PPP1R14A, protein phosphatase-1 inhibitor subunit 14A, & mapping human PPP1R14A to chromosome 19q13.13-q13.2”. Mol. Biol. Rep. 28 (2): 91–101. doi:10.1023/A:1017998029053. PMID 11931393.
- Dubois T, Howell S, Zemlickova E, Aitken A (2002). “Identification of casein kinase Ialpha interacting protein partners”. FEBS Lett. 517 (1–3): 167–71. doi:10.1016/S0014-5793(02)02614-5. PMID 12062430.
- Strausberg RL, Feingold EA, Grouse LH, et al. (2003). “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences”. Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
- Liu QR, Zhang PW, Lin Z, et al. (2004). “GBPI, a novel gastrointestinal- and brain-specific PP1-inhibitory protein, is activated by PKC and inactivated by PKA”. Biochem. J. 377 (Pt 1): 171–81. doi:10.1042/BJ20030128. PMC 1223837. PMID 12974676.
- Eto, M., Kitazawa, T., and Brautigan, D.L. (2004). “Phosphoprotein inhibitor CPI-17 specificity depends on allosteric regulation of protein phosphatase-1 by regulatory subunits”. Proc. Natl. Acad. Sci. USA. 101 (24): 8888–93. doi:10.1073/pnas.0307812101. PMC 428442. PMID 15184667.
- Zemlickova E, Johannes FJ, Aitken A, Dubois T (2004). “Association of CPI-17 with protein kinase C and casein kinase I”. Biochem. Biophys. Res. Commun. 316 (1): 39–47. doi:10.1016/j.bbrc.2004.02.014. PMID 15003508.
- Kolosova IA, Ma SF, Adyshev DM, et al. (2004). “Role of CPI-17 in the regulation of endothelial cytoskeleton”. Am. J. Physiol. Lung Cell Mol. Physiol. 287 (5): L970–80. doi:10.1152/ajplung.00398.2003. PMID 15234908.
- Gerhard DS, Wagner L, Feingold EA, et al. (2004). “The Status, Quality, and Expansion of the NIH Full-Length cDNA Project: The Mammalian Gene Collection (MGC)”. Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMC 528928. PMID 15489334.
- Jin H, Sperka T, Herrlich P, Morrison H (2006). “Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase”. Nature. 442 (7102): 576–9. doi:10.1038/nature04856. PMID 16885985.
- Morin C, Sirois M, Echave V, et al. (2007). “Epoxyeicosatrienoic acid relaxing effects involve Ca2+-activated K+ channel activation and CPI-17 dephosphorylation in human bronchi”. Am. J. Respir. Cell Mol. Biol. 36 (5): 633–41. doi:10.1165/rcmb.2006-0281OC. PMID 17237191.
- Lartey J, Smith M, Pawade J, et al. (2007). “Up-regulation of myometrial RHO effector proteins (PKN1 and DIAPH1) and CPI-17 (PPP1R14A) phosphorylation in human pregnancy is associated with increased GTP-RHOA in spontaneous preterm labor”. Biol. Reprod. 76 (6): 971–82. doi:10.1095/biolreprod.106.058982. PMID 17301291.
- Eto M.; Kitazawa T.; et al. (2007). “Phosphorylation-induced conformational switching of CPI-17 produces a potent myosin phosphatase inhibitor”. Structure. 15 (12): 1591–602. doi:10.1016/j.str.2007.10.014. PMC 2217667. PMID 18073109.
- Dimopoulous, G. J., Semba, S.; et al. (2007). “Ca2+-Dependent Rapid Ca2+ Sensitization of Contraction in Arterial Smooth Muscle”. Circ. Res. 100 (1): 121–29. doi:10.1161/01.RES.0000253902.90489.df. PMC 2212616. PMID 17158339.
- Kim, J.I., Young, G.D.; et al. (2009). “Expression of CPI-17 in smooth muscle during embryonic development and in neointimal lesion formation”. Histochem. Cell Biol. 132 (2): 191–8. doi:10.1007/s00418-009-0604-2. PMC 2878480. PMID 19437030.
- Kitazawa, T., Semba, S.; et al. (2009). “Nitric oxide-induced biphasic mechanism of vascular relaxation via dephosphorylation of CPI-17 and MYPT1”. J. Physiol. 587 (Pt14): 3587–603. doi:10.1113/jphysiol.2009.172189. PMC 2742283. PMID 19470783.